Spotlight on the
news
of the Cimi

“Exploring the microbiome to displace multi-drug resistant Enterobacteria from the gut”

« Identification of key components of proteostasis regulation for diagnosis and targeting of inflammatory diseases and cancer »

« Malaria, asplenia : a story of sensing, swelling, sickling & pitting »

« Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses »

Residency and trafficking of ILC2 under stable and Th2-induced inflammatory conditions

“Lower disease activity but higher risk of severe COVID- 19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α”

New Publication – Allon Weiner’s team

Trans-cellular tunnels induced by the fungal pathogen Candida albicans facilitate invasion through successive epithelial cells without host damage. Lachat J., Pascault A., Thibaut D., Le Borgne R., Verbavatz J.M., Weiner A. Nat Commun 13, 3781 (2022). Free PMC Article.

The effectiveness of a vaccine against #HIV

Dr Behazine Combadière, a lead investigator at the Centre for Immunology and Infectious Diseases @INSERM is working on predicting the effectiveness of a vaccine against #HIV which is concurrently advancing the #CovidVaccine development research.

Vaccine responses against SARS-CoV-2 variants examined in people with lupus

The majority of people with systemic lupus erythematosus (SLE) who respond to messenger (m)RNA COVID-19 vaccines also generate an antibody response against emerging SARS-CoV-2 variants, albeit with reduced neutralizing activity against variants bearing the E484K mutation, researchers report.

Is it dangerous to be vaccinated if you have already had the coronavirus?

A message received by the editorial staff of LCI.fr is concerned about the possible danger of a vaccine against Covid-19 for people already infected. We respond with Béhazine Combadière, director of research at Inserm.

Covid-19: a needle-free vaccination soon possible?

To meet the demand for vaccines, and to avoid a possible shortage of needles and syringes, start-ups, with the support of certain countries such as Canada, are working on injection methods that are not intramuscular, but through the skin.